Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12985919 | 1.00 | CTSK (0.45) | CTSKALDH1A1CD274SMN1; SMN2KDM4E | |
| SCHEMBL21230528 | 1.00 | CTSK (0.45) | CTSKALDH1A1CD274SMN1; SMN2KDM4E | |
| SCHEMBL8903360 | 0.83 | TSHR (0.39) | CTSKALDH1A1CD274SMN1; SMN2KDM4E | |
| SCHEMBL22988104 | 0.81 | CD274 (0.52) | CTSKALDH1A1CD274JAK2TDP1 | |
| SCHEMBL13160615 | 0.81 | CD274 (0.52) | CTSKALDH1A1CD274JAK2TDP1 | |
| SCHEMBL4984224 | 0.80 | CTSK (0.47) | CTSKALDH1A1CD274SMN1; SMN2CTSL | |
| SCHEMBL4984232 | 0.80 | CTSK (0.47) | CTSKALDH1A1CD274SMN1; SMN2CTSL | |
| SCHEMBL12014420 | 0.78 | ATM (0.48) | ALDH1A1SMN1; SMN2KDM4EHPGDATM | |
| SCHEMBL25669794 | 0.78 | HRH3 (0.50) | ALDH1A1SMN1; SMN2KDM4EHPGDATM | |
| SCHEMBL10164354 | 0.77 | CTSK (0.43) | CTSKCD274SMN1; SMN2CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383932-A1 | Phenol Prodrugs | HARP BIO INC. | 2024-11-21 | — | — | US | disclosed |
| US-20210380626-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | MAVERIX ONCOLOGY, INC. | 2021-12-09 | — | — | US | disclosed |
| WO-2019152911-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | EVERETT STEVEN ALBERT (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2010146299-A1 | AZETIDINE-DERIVED ESTERS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS CANNABINOID RECEPTOR MODULATORS | SANOFI-AVENTIS (FR) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380626-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | ZYX, KRAS, SLC7A5 | CTSK 3518/4885ALDH1A1 3278/4885CD274 1450/4885 |
| US-20240383932-A1 | Phenol Prodrugs | CFTR, PAH, CYP1A1 | CTSK 1211/4885ALDH1A1 644/4885CD274 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.